Fig. 2
From: Targeting TIGIT for cancer immunotherapy: recent advances and future directions
The expression of TIGIT can be influenced by a variety of factors. Notably, Interferon-I (IFN-I), chemotherapy agents, GITR antibodies, and 1α,25-Dihydroxyvitamin D3 (1α,25(OH)(2)D(3)) have been observed to downregulate its expression. In contrast, microwave ablation, glucose deprivation, hypoxic conditions, as well as the presence of CCL23, IL-10, inhaled IL-15, and anti-PD-1/PD-L1 therapies have been found to enhance the expression of TIGIT, thereby contributing to an immunosuppressive TME